). This report describes cis-acting regulatory elements in the LTR that control viral gene expression. A series of LTR mutants and hybrid promoter constructs have been analyzed in transient expression assays for responsiveness to Taf. The targets for transactivation have been mapped to two regions of the U3 domain of the LTR, between positions -1196 and -880 and between positions -403 and -125 (+ 1 represents the transcription initiation site). No significant nucleotide sequence homology between these two regions is noted; thus, the SFV-1 taf gene acts through at least two distinct sequence elements in the LTR. The target contained between positions -403 and -125 acts independently of orientation, in different cell types and species, and in the context of a heterologous promoter. Thus, the target element between positions -403 and -125 has properties of a transcriptional enhancer. The observation that two distinct elements in the SFV-1 LTR are targets for transcriptional transactivation is novel with respect to observations for other retroviral systems. The R-U5 region of the SFV-1 LTR down-regulates transactivation by severalfold. Computer analysis of the R-U5 region revealed a secondary structure with a free-energy level of -74 kcal (ca. -310,000 J); this structural feature may account for the inhibitory effect on gene expression directed by the LTR. Taf of SFV-1 had no effect on gene expression directed by the LTR of the related human foamy virus, whereas Taf transactivates gene expression directed by the LTRs of the human and simian immunodeficiency viruses. Comparative functional analysis of Taf on homologous and heterologous LTRs may facilitate elucidation of the mechanism of transactivation of foamy viruses.
Retroviruses are classified into seven genera, one of which contains the spumaviruses. Spumaviruses, also known as foamy viruses, have been recovered from several mammalian species, including human, simian, bovine, feline, and murine species (13, 32) . The simian foamy virus type 1 (SFV-1), an isolate from a rhesus macaque (14) , has been molecularly cloned, and the genome has been completely sequenced ( Fig. 1) (20, (22) (23) (24) . In addition to the genes gag, pol, and env, the genome of SFV-1 contains two open reading frames (ORFs) at the 3' end of env, extending into the 3' long terminal repeat (LTR). SFV-1 encodes three species of viral mRNA: an 11.5-kb RNA representing the full-length transcript, a 6.5-kb RNA representing the env message, and a 2.8-kb RNA from the ORF region (24) . The ORF region of SFV-1 is specified by messages that involve multiple splicing events (24) . The first ORF, designated taf (transcriptional transactivator of foamy virus), activates gene expression directed by the homologous LTR (23, 24) . A related human foamy virus (HFV) encodes the virion gag, pol, and env proteins, as well as three large ORFs (bel-1, bel-2, and bel-3) which extend from the 3' end of env into the 3' LTR (7, 19) . Transcripts for the bel region of HFV are also generated by complex splicing events (25) . The bel-l gene of HFV also has a transactivator function (15, 37) . bel-J of HFV (also designated tanl shows 39% homology with the predicted amino acid sequence of SFV-1 taf (24) . bel-1 has been shown to be essential for virus replication in vitro (18) . Translation frames encoding bel-2 and ORF-2 have 38% * Corresponding author. homology at the amino acid level (24) ; the potential function of these genes is not known. SFV-1 does not specify a translation frame that corresponds to bel-3 of HFV (24) . LTR sequences of these two primate foamy viruses differ significantly in the U3 domain (24% nucleotide homology); this domain encompasses the cis-acting target element for the viral taf genes (15, 23, 24, 37, 41) . In contrast, the R-U5 domains of both viral LTRs show 85% homology (23) . The fact that the U3 domains of the LTRs and the taf genes diverge greatly implies that target sequences for transactivation in the two viruses may be distinct.
To define the target for Taf, several deletion mutants of the SFV-1 LTR were constructed. Also, hybrid promoters containing portions of the SFV-1 LTR and both the herpes simplex virus (HSV) thymidine kinase (tk) promoter and the simian virus 40 (SV40) early promoter were made. By using transient expression assays, the target for transactivation was mapped to two regions in the U3 domain of the LTR. In addition, the R-U5 region of the LTR was shown to downregulate transactivation.
MATERIALS AND METHODS
Cell cultures. chloramphenicol acetyltransferase (CAT) gene, has been described previously (23) . Deletion mutants of the SFV-1 LTR were constructed by using appropriate restriction enzymes and placed upstream from the CAT gene in an expression vector. The constructions of pSFV-1 LTR/CAT 41, pSFV-1 LTR 46, pSVORF-1, pHFV 5'LTR/CAT, pH TLV-I LTR/CAT, pHIV LTR/CAT, pSIV LTR/CAT, pS Vtat(HIV), pSVtat(SIV), pHTLV LTR/tax, and ptk/CAT are described elsewhere (3, 24, 28, 34, 36 (COS-7 and L929). pSFV-1 LTR/CAT and the HSV tk promoter expressing CAT (ptk/cat) were controls to compare levels of transactivation. Plasmids containing the hybrid promoters demonstrated CAT activities severalfold higher than that of the tk promoter directing CAT; thus, the regions between positions -1196 and -880 and between -403 and -125 are necessary and sufficient for transactivation by taf (Fig. 3) . The sequence between positions -1196 and -880 functions only in the sense orientation, whereas the latter sequence (-403 to -125) responds to Taf irrespective of orientation (Fig. 3) . (HTLV-I), human immunodeficiency virus type 1 (HIV-1), and simian immunodeficiency virus (SIV). taf had no effect on the HTLV-I LTR, whereas taf transactivates CAT expression directed by the SIV LTR and the HIV-1 LTR 11-fold and 12-fold, respectively ( Table 1) . Tat of SIV and HIV-1 and Tax of HTLV-I did not transactivate gene expression directed by the LTR of SFV-1 (Table 1) .
Negative regulatory effect of the R-U5 sequences. Additional deletion mutants were constructed in the R-U5 domain of the LTR to determine whether other cis-acting regulatory regions are present in the SFV-1 LTR. Deletion of the R-U5 region of the LTR shows basal-level CAT activity similar to that found in the wild-type LTR. The LTR devoid of the R-U5 sequences directed CAT expression to a level 218-fold higher in cells cotransfected with the plasmid expressing taf (Fig. 4) . This value is at least 11-fold more than the level of transactivation observed with the wild-type LTR. Thus, the R-U5 of SFV-1 has a negative regulatory function. Deletion of the LTR from the 5' end up to position -270 and the R-U5 region showed transactivation levels greater than that of the wild-type LTR (Fig. 4) .
To determine whether the R-U5 region of SFV-1 LTR has an inhibitory role on a heterologous promoter, this region was cloned in both orientations downstream from the SV40 promoter in an expression vector. Both orientations of R-U5 lowered the levels of CAT by at least 10-fold with two different cell lines (COS-7 and CV-1) (Fig. 5) . A control DNA sequence about the size of the R-U5 region showed no inhibition of CAT expression directed by the SV40 promoter; thus, the negative effect of R-U5 is not due to the increased distance of the CAT gene from the promoter.
DISCUSSION
A previous report revealed that the taf gene of SFV-1 encodes a transcriptional transactivator which augments gene expression directed by the viral LTR (23, 24) . In this report, we have mapped the target for Taf to two regions in the U3 domain of the LTR, between positions -1196 and -880 and between positions -403 and -125; transactivation is mediated by the second region in both orientations. Furthermore, we have shown that the R-U5 domain of the SFV-1 LTR down-regulates transactivation. Studies with heterologous LTRs revealed that taf has no effect on the HFV and HTLV-I LTRs. However, the taf gene of SFV-1 transactivates gene expression directed by the SIV and HIV-1 LTRs.
Lentiviruses (e.g., HIV-1, HIV-2, SIV, visna maedi virus, and equine infectious anemia virus) and certain oncoviruses (e.g., HTLV-I, HTLV-II, and bovine leukemia virus) also encode transactivators which require target elements in the LTR (9, 27, 33, 39) . Transactivation by the HIV tat gene product regulates accumulation of viral transcripts through a target element in the LTR located immediately downstream from the cap site; efficient transactivation depends on the specific sequence, secondary structure, location, and orientation of the target element (4, 5, 16, 33, 39) . In HTLV-I, a transactivator gene that encodes a protein, designated p4Otax, regulates viral replication at the transcriptional level through three 21-bp direct repeats in the LTR (8, 31, 40) . The fact that SFV-1 has no significant homology with lentivirus and oncovirus LTRs and with transactivators suggests that the mechanism of the transcriptional transactivator is different from that of other retroviruses. Several experiments have implicated the involvement of host cell DNA-binding proteins in transactivation in the HIV and HTLV systems (1, 6, 8, 29, 30, 38) . The precise role of host proteins in transactivations by tat, tax, and taf remains to be determined. Inspection of the transactivator target regions of SFV-1 revealed an AP-1 motif (TGACTCA) at position -225. In visna maedi virus, the AP-1 binding sites in the U3 domain of the LTR are critical for transactivation by visna maedi virus Tat, (12) . The AP-1 motif(s) mediates transcription induction by phorbol esters (17) . Interestingly, studies with Jurkat cells of cell activation by both protein kinase C and the cyclic AMP-dependent protein kinase pathways revealed no activation of SFV-1 LTR (our unpublished results). In addition, deletion from the 5' end to position -270 substantially reduced transactivation, compared with deletion from the 5' end to position -403; accordingly, the role of the putative AP-1 site, if any, is minor. Furthermore, the lack of known cis-acting regulatory sequences, other than the putative AP-1 binding sequence at -225, in the target regions implies a novel transactivation mechanism. Since both orientations of the major cis-acting region are active, one possible mechanism of transactivation in SFV-1 may be similar to that of transcriptional enhancer elements.
Studies of Taf activity on heterologous LTRs may shed light on the mechanism of transactivation. The taf genes of both SFV-1 and HFV activate the gene expression-directed HIV LTR in the COS-7 cell line. However, Taf of SFV-1 has no effect on the HFV LTR; also, HFV Taf does not activate the SFV-1 LTR (35) . The lack of cross-transactivation is not surprising, because of a high degree of sequence divergence between the U3 domains of the LTRs; the taf genes also show a very low level of homology. The mechanism by which Taf transactivates SIV and HIV LTRs remains to be determined. Taf acts through a target in the U3 domain of the HIV LTR, whereas the target for Tat is in the R-U5 portion of the HIV LTR (21 Rex (10) . The observation that the R-U5 region of the SFV-1 LTR has an inhibitory effect in both orientations suggests that the mechanism of down-regulation may involve secondarystructure features of viral RNA. In fact, computer analysis of the R-U5 region revealed a secondary structure with a free-energy level of -74 kcal (ca. -310,000 J) (Fig. 6) . In transient expression assays, plasmids expressing ORF-2 or taflORF-2 or a cDNA from SFV-1-infected cells that is equivalent to bet of HFV (25) failed to relieve the inhibitory action of the R-U5 region on transactivation (our unpublished results). The significance and mechanism of downregulation of transactivation by R-U5 in SFV-1 replication remain to be determined. Alternatively, the polyadenylation signal or some other cis-acting element in the 5' LTR may be involved in premature transcription termination, possibly via the secondary structure of R-U5. Mutational analysis is required to determine whether the secondary structure and/or the polyadenylational signal plays a role in negative regulation of gene expression directed by the SFV-1 LTR.
The investigations described in this report provide a basis for understanding the mechanism of transactivation of 
